文献速递中枢神经肿瘤放疗头颈部肿瘤放疗胸部肿瘤放疗

过去二十年国家临床试验网络放疗试验中患者报告结局的使用分析

Analysis of Patient-Reported Outcome Utilization Within National Clinical Trials Network Cooperative Group Radiation Oncology Trials Over the Past 2 Decades.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-12-13

该横断面研究分析了过去二十年国家临床试验网络合作组放疗2期和3期试验中患者报告结局(PRO)的使用频率,并通过文献综述评估PRO数据的发表情况。EQ-5D系列问卷最常用(22.8%)。文献综述显示PRO数据与生存终点共同发表的比例随时间增加。

要点

  • 56.4%的放疗试验在设计时纳入了PRO,脑和头颈试验比例最高。
  • EQ-5D系列问卷是最常用的PRO工具,占22.8%。
  • PRO数据与生存数据共同发表的比例随时间增加。

核心结论

  • 放疗领域在过去二十年已接纳将PRO纳入多中心高影响力临床试验,并增加了PRO数据与生存数据共同发表。

研究设计与样本

  • 横断面研究分析过去二十年国家临床试验网络合作组放疗2期和3期试验中PRO的使用频率。
  • 通过文献综述评估PRO数据的发表结局,仅纳入设计中使用了PRO且已有发表结果的成熟试验。

主要发现

  • 脑和头颈试验PRO纳入比例最高(81.8%和76.9%),胸部和乳腺试验最低(18.8%和37.5%)。
  • EQ-5D系列问卷是最常用的PRO工具,用于22.8%的试验。
  • 文献综述显示PRO数据与生存终点共同发表的比例随时间增加。

临床怎么用

  • 支持在放疗临床试验中常规纳入PRO以评估生活质量,并促进PRO数据与生存数据共同发表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: When treating cancer, both quantity and quality of life are valuable, though oncology trials have long placed greater emphasis on the former. The goal of this work was to evaluate how patient-reported outcomes (PROs) have been incorporated into radiation therapy trials within the National Clinical Trials Network over the last 2 decades to measure quality of life and to assess how PRO data have been disseminated in publications upon trial conclusion. METHODS AND MATERIALS: This cross-sectional study analyzed the frequency of use of PROs in National Clinical Trials Network cooperative group radiation therapy phase 2 and 3 clinical trials over the past 2 decades. A literature review was performed to determine the publication outcomes of PRO data, including only trials that used PROs in their design and were mature enough to have published results. RESULTS: Fifty-seven (56.4%) of the 101 trials included in this study included PROs in their design. Brain and head and neck trials demonstrated the largest proportional incorporation of PROs (81.8% and 76.9%, respectively), and thoracic and breast trials used the fewest (18.8% and 37.5%, respectively). The EQ-5D family of questionnaires was the most commonly used PROs, used in 22.8% of trials included. The literature review demonstrated a pattern of increased publication of PRO data alongside survival endpoints in manuscripts derived from these trials over time. CONCLUSIONS: Though there is room for improvement, the field of radiation oncology has embraced the incorporation of PROs into multicenter, high-impact clinical trials over the past 2 decades and has increased its publication of this data alongside survival data from these trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Howell JN, Anker CJ, Walker AJ, et al. Analysis of Patient-Reported Outcome Utilization Within National Clinical Trials Network Cooperative Group Radiation Oncology Trials Over the Past 2 Decades. Int J Radiat Oncol Biol Phys. 2020. PMID: 33321191. doi:10.1016/j.ijrobp.2020.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。